The global biomarkers market size is expected to reach over
USD 118 billion by 2026, according to a new study by Grand View Research Inc.
It is projected to expand at a CAGR of 13.7% during the forecast period.
Technological advancements, high consumer awareness, and increasing funds for
research and development (R&D) activities are collectively propelling the
market growth.
Drug discovery was estimated to be one
of the highest revenue generating segments of the market. Pharmaceutical
companies are undertaking extensive R&D initiatives to develop targeted
therapeutics. Coordinated research efforts on biomarker development is a rising
trend among commercial R&D organizations, academic research institutions,
federal government biomedical regulatory and research agencies, and
nonprofitable health foundations.
North America led the biomarker market
in 2018, driven by high disease prevalence, proactive governmnet initiatives,
and substantial demand for personalized medicines. North America is anticipated
to retain its leading position throughout the forecast period. Asia Pacific is
expected to witness the fastest regional growth, spearheaded by India.
Some key players operating in the
biomarkers market include F. Hoffmann-La Roche Ltd.; Abbott.; Epigenomics AG;
Agilent Technologies, Inc.; Johnson & Johnson Services, Inc; Siemens
Healthcare Private Limited; Bio-Rad Laboratories, Inc.; Thermo Fisher
Scientific, Inc.; and Qiagen. Key players are developing novel kits and
therapies or drugs to target population in the areas with high unmet clinical
needs.
Browse full research report on Biomarkers Market: https://www.grandviewresearch.com/industry-analysis/biomarkers-industry
Further key findings from the study suggest:
- Safety biomarkers held the largest market share of over 42%
in 2018 due to reduction in drug attrition and increasing awareness of
routine healthcare checkups
- Validation biomarkers is estimated to be one of the fastest
growing segments
- Personalized medicine is estimated to grow at a CAGR of 15.0%
over the forecast period owing to growing consumer awareness
- Cancer held the largest market share in 2018, driven by an
increase in global prevalence of cancer and the presence of a strong pipeline
of drugs
- Cardiovascular diseases is projected to be the fastest
growing segment throughout the forecast period, supported by sedentary
lifestyles and growing obese population.
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/biomarkers-industry/request/rs1
Grand View Research has segmented the global biomarkers market on
the basis of application, type, and region:
Biomarkers Type Outlook (Revenue, USD Million, 2014 - 2026)
- Safety
- Efficacy
- Validation
Biomarkers Application Outlook (Revenue, USD Million, 2014 - 2026)
- Diagnostic
- Drug
Development
- Personalized
Medicine
- Others
Biomarkers Disease Outlook (Revenue, USD Million, 2014 - 2026)
- Cancer
- Cardiovascular
Diseases
- Neurological
Diseases
- Immunological
Diseases
- Others
Biomarkers Regional Outlook (Revenue, USD Million, 2014 - 2026)
- North
America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Spain
- France
- Italy
- Asia
Pacific
- Japan
- China
- India
- South
Korea
- Australia
- Latin
America
- Brazil
- Mexico
- Argentina
- MEA
- South
Africa
- Saudi
Arabia
- UAE
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For
more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment